EPO and stroke disorder: The increased risk of thrombosis and stroke associated with EPO administration (39, 40, 42–44) prompted researchers to design asialoerythropoietin, a desialytated version of recombinant EPO notable for its shorter half-life which allowed for its neuroprotective effects with limited effects on erythrocyte mass (45).